Sequenced from PBMCs from a donor who had recovered from a naturally-occurring MPXV infection
≥ 5.0 mg/ml
< 1.0 EU/mg as determined by the LAL method
≥95% monomer by analytical SEC
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Standard Overnight on Blue Ice.
Other Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Anti-MPXV B6R (clone name: MPXV-13) is reactive against the EV membrane protein encoded by ORF B6R of monkeypox virus (Homologous to Vaccinia virus B5R). This antibody also reacts to VACV antigen and lysate, CPXV lysate, MPXV lysate, and VARV antigen and lysate. MPXV-13 weakly binds to VACV purified antigen, VACV and MPXV virus-infected cell lysates, and strongly binds VARV purified antigen and CPXV virus-infected cell lysate. MPXV-13 neutralizes VACV EV plus complement (+C’) but not MV, MV+C’, or EV. MPXV-13 also binds to CPXV EV+C’ but not EV. MPXV-13 does not neutralize MPXV MV, MV+C’, EV, or EV+C’.
Complementary screening approaches were used to identify orthopoxvirus-specific mAbs to MPXV, cowpox virus (CPXV), variola virus (VARV), and vaccinia virus (VACV).
B5 is a surface antigen on the enveloped virion.
Monkeypox virus (MPXV) is a zoonotic member of the Orthopoxvirus genus in the Poxviridae family1. It is the next most pathogenic poxvirus after smallpox. Two genetic clades, West African and Central African (Congo Basin), have been characterized; the latter is capable of human-to-human transmission1,2. Monkeypox has gained clinical relevance due to the eradication of smallpox, which has created opportunities for increased prevalence and viral mutations that may affect virulence1, 2. Rodents are thought to be the natural reservoir, with transmission through contact with bodily fluids and feces. Case fatality rates are <1% and up to 11% for the West African and Central Basin clades, respectively1,2. An infection with one orthopoxvirus of any one species, or vaccinia virus vaccination, protects against infection by other orthopoxviruses3,4,5.
MPXV is an enveloped virus with a linear, double-stranded DNA genome2 and a large, complex proteome of over 200 proteins6. During infection, the virus exists in two antigenically distinct forms: mature virions (MV) or enveloped virions (EV)6.
References & Citations
1. Sklenovská N, Van Ranst M. Front Public Health. 6:241. 2018.
2. Moore M, Zahra F. 2021 Oct 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.
3. McConnell S, Herman YF, Mattson DE, et al. Am J Vet Res. 25:192-195. 1964.
4. Hammarlund E, Lewis MW, Carter SV, et al. Nat Med. 11(9):1005-1011. 2005.
5. Gilchuk I, Gilchuk P, Sapparapu G, et al. Cell. 167(3):684-694.e9. 2016.
6. Moss B. Immunol Rev.239:8–26. 2011.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.